{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:15:38Z","timestamp":1765779338481,"version":"3.48.0"},"reference-count":35,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,3]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Disease-modifying therapies (DMTs) can slow disease progression in multiple sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) progression among newly diagnosed people with MS in relation to the first DMT received.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>A cohort study using data from nationwide registers in Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>People with MS (PwMS) in Sweden first diagnosed in 2006\u20132015, when aged 20\u201355, receiving first-line therapy with interferons (IFN), glatiramer acetate (GA) or natalizumab (NAT). They were followed up through 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Outcomes (in Euros, \u20ac) were: (1) secondary healthcare costs: specialised outpatient and inpatient care including out-of-pocket expenditure, DMTs including hospital-administered MS therapies, and prescribed drugs, and (2) productivity losses: sickness absence and disability pension. Descriptive statistics and Poisson regression were computed, adjusting for disability progression using the Expanded Disability Status Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>3673 newly diagnosed PwMS who were treated with IFN (N=2696), GA (N=441) or NAT (N=536) were identified. Healthcare costs were similar for the INF and GA groups, while the NAT group had higher costs (p value&lt;0.05), owing to DMT and outpatient costs. IFN had lower productivity losses than NAT and GA (p value&gt;0.05), driven by fewer sickness absence days. NAT had a trend towards lower disability pension costs compared with GA (p value&gt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Similar trends over time for healthcare costs and productivity losses were identified across the DMT subgroups. PwMS on NAT maintained their work capacity for a longer time compared with those on GA, potentially leading to lower disability pension costs over time. COI serves as an objective measure to explore the importance of DMTs in maintaining low levels of progression of MS over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-067516","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T10:03:17Z","timestamp":1684231397000},"page":"e067516","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-1865","authenticated-orcid":false,"given":"Korinna","family":"Karampampa","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-5162","authenticated-orcid":false,"given":"Hanna","family":"Gyllensten","sequence":"additional","affiliation":[{"name":"Institute of Health and Care Sciences, University of Gothenburg, Goteborg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-4275","authenticated-orcid":false,"given":"Chantelle","family":"Murley","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrius","family":"Kavaliunas","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-6732","authenticated-orcid":false,"given":"Jan","family":"Hillert","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Alexanderson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"2025121422125886000_13.5.e067516.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2010.09.005"},{"key":"2025121422125886000_13.5.e067516.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108599","article-title":"High nationwide incidence of multiple sclerosis in Sweden","volume":"9","author":"Ahlgren","year":"2014","journal-title":"PLoS One"},{"key":"2025121422125886000_13.5.e067516.3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10198-017-0894-6","article-title":"Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age","volume":"19","author":"Gyllensten","year":"2018","journal-title":"Eur J Health Econ"},{"key":"2025121422125886000_13.5.e067516.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159129","article-title":"Cost of illness of multiple sclerosis-a systematic review","volume":"11","author":"Ernstsson","year":"2016","journal-title":"PLoS One"},{"key":"2025121422125886000_13.5.e067516.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317509"},{"key":"2025121422125886000_13.5.e067516.6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40273-017-0577-2","article-title":"Disease-Modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies","volume":"36","author":"Iannazzo","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2025121422125886000_13.5.e067516.7","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12425"},{"key":"2025121422125886000_13.5.e067516.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-016-0117-y"},{"key":"2025121422125886000_13.5.e067516.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the rx-risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"2025121422125886000_13.5.e067516.10","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515616205"},{"key":"2025121422125886000_13.5.e067516.11","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.41.2_Part_1.332","article-title":"Edss reliability","volume":"41","author":"Goodkin","year":"1991","journal-title":"Neurology"},{"key":"2025121422125886000_13.5.e067516.12","unstructured":"Drummond MF , Sculpher MJ , Claxton K , et al . Methods for the economic evaluation of health care programmes. Oxford University Press, 2015."},{"key":"2025121422125886000_13.5.e067516.13","unstructured":"National Insurance Agency [F\u00f6rs\u00e4kringskassan] . Social insurance in figures 2017. 2017."},{"key":"2025121422125886000_13.5.e067516.14","unstructured":"Eurostat . HICP-all items-annual average indices (2015=100). n.d. Available: https:\/\/ec.europa.eu\/eurostat\/tgm\/table.do?tab=table&init=1&language=en&pcode=tec00027&plugin=12019"},{"key":"2025121422125886000_13.5.e067516.15","doi-asserted-by":"crossref","unstructured":"Moore DS . Tests of chi-squared type. Goodness-of-Fit-Techniques Routledge 2017:63\u201396. doi:10.1201\/9780203753064","DOI":"10.1201\/9780203753064-3"},{"key":"2025121422125886000_13.5.e067516.16","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2015.68.6.540"},{"key":"2025121422125886000_13.5.e067516.17","doi-asserted-by":"crossref","unstructured":"McCullagh P , Nelder JA . Generalized linear models. Boston, MA, 1989. doi:10.1007\/978-1-4899-3242-6","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"2025121422125886000_13.5.e067516.18","article-title":"Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden","volume":"5","author":"Gyllensten","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025121422125886000_13.5.e067516.19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s41669-019-0150-3","article-title":"Healthcare, sickness absence, and disability pension cost trajectories in the first 5 years after diagnosis with multiple sclerosis: a prospective register-based cohort study in Sweden","volume":"4","author":"Karampampa","year":"2020","journal-title":"PharmacoEconomics Open"},{"key":"2025121422125886000_13.5.e067516.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001608"},{"key":"2025121422125886000_13.5.e067516.21","unstructured":"Piehl F , Olsson T , Lycke J , et al . L\u00e4kemedelsbehandling AV multipel skleros (MS) \u2013bakgrundsdokumentation. n.d. Available: https:\/\/lakemedelsverket.se\/upload\/halso-och-sjukvard\/behandlingsrekommendationer\/bakg_dok\/Lakemedelsbehandling_av_multipel_skleros_MS_bakgrundsdokumentation_webb.pdf"},{"key":"2025121422125886000_13.5.e067516.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1162-9","article-title":"Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages","volume":"18","author":"Melendez-Torres","year":"2018","journal-title":"BMC Neurol"},{"key":"2025121422125886000_13.5.e067516.23","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000227"},{"key":"2025121422125886000_13.5.e067516.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-115","article-title":"Social participation in patients with multiple sclerosis: correlations between disability and economic burden","volume":"14","author":"Kwiatkowski","year":"2014","journal-title":"BMC Neurol"},{"key":"2025121422125886000_13.5.e067516.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.07.010"},{"key":"2025121422125886000_13.5.e067516.26","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurol"},{"key":"2025121422125886000_13.5.e067516.27","unstructured":"Swedish Neuroregistries - Multiple Sclerosis . Visualisation and analysis platform (VAP) for multiple sclerosis-coverage ratio broken down by County, gender and the last follow-up date [ T\u00e4ckningsgrad uppdelat f\u00f6r l\u00e4n, k\u00f6n och sista uppf\u00f6ljningsdatum ], coverage ratio against the patient register, by year [ T\u00e4ckningsgrad mot patientregistret, \u00e5r ]. 2019. Available: https:\/\/www.neuroreg.se\/en.html\/multiple-sclerosis-realtime-data-and-results-vap"},{"key":"2025121422125886000_13.5.e067516.28","unstructured":"Economic statistics - KPP Somatik - SKL . Swedish association of local authorities and regions [Sveriges Kommuner och Landsting]. Available: https:\/\/skl.se\/ekonomijuridikstatistik\/statistik\/kostnadperpatientkpp\/kppsomatik.1077.html2019"},{"key":"2025121422125886000_13.5.e067516.29","unstructured":"Swedish association of local authorities and regions [ sveriges kommuner och landsting ]. economic statistics-patientavgifter fr.o.m. 2018. Available: https:\/\/skl.se\/download\/18.3ee4cc4f1611af77b89179dd\/1517495154691\/avgift_%C3%B6ppenv%C3%A5rd_inkl.missiv_slutenavg18_19jan18.pdf"},{"key":"2025121422125886000_13.5.e067516.30","unstructured":"V\u00e5rdguiden . Patient fees in V\u00e4stra G\u00f6taland County in Sweden [patientavgifter I V\u00e4stra G\u00f6taland]. 2018. Available: https:\/\/www.1177.se\/Vastra-Gotaland\/Regler-och-rattigheter\/Patientavgifter-i-Vastra-Gotaland\/"},{"key":"2025121422125886000_13.5.e067516.31","unstructured":"FASS.se . Tysabri. n.d. Available: https:\/\/www.fass.se\/LIF\/product?nplId=20040916001115&userType=0&docType=6&scrollPosition=751.33331298828122019"},{"key":"2025121422125886000_13.5.e067516.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331"},{"key":"2025121422125886000_13.5.e067516.33","unstructured":"FASS.se . Rituximab-price. n.d. Available: https:\/\/www.fass.se\/LIF\/product?userType=2&nplId=19980602000029&docType=30&scrollPosition=600s2019"},{"key":"2025121422125886000_13.5.e067516.34","unstructured":"Statistics Sweden . Genomsnittlig m\u00e5nadsl\u00f6n 1973\u20132018. n.d. Available: https:\/\/www.scb.se\/hitta-statistik\/statistik-efter-amne\/arbetsmarknad\/loner-och-arbetskostnader\/lonestrukturstatistik-privat-sektor-slp\/pong\/tabell-och-diagram\/genomsnittlig-manadslon-1973-\/2019"},{"key":"2025121422125886000_13.5.e067516.35","unstructured":"Swedish Tax Authority [Skatteverket] . Belopp och procent f\u00f6r \u00e5ren 2019-2004-privat. 2019. Available: https:\/\/www.skatteverket.se\/privat\/skatter\/beloppochprocent.4.18e1b10334ebe8bc80004109.html"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-067516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:13:06Z","timestamp":1765779186000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-067516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,16]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-067516"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-067516","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}